新生儿血清抗gbs2106蛋白免疫球蛋白G(IgG)与婴儿早期侵袭性B族链球菌病风险降低的关联
在南非出生队列中嵌套病例对照研究,评估新生儿血清抗gbs2106 IgG与90天内侵袭性B族链球菌病风险的关系。gbs2106基因存在于所有定植和侵袭分离株,蛋白表达率分别为81.6%(71/87)和82.2%(48/58)。病例组婴儿抗gbs2106 IgG几何平均浓度低于对照组(158.7 AU/ml vs 304.8 AU/ml,p=0.012),提示gbs2106蛋白为潜在疫苗候选。
要点
- gbs2106基因存在于所有定植和侵袭性B族链球菌分离株。
- 母血与脐血抗gbs2106 IgG强正相关(r=0.855,p<0.0001)。
- 病例组婴儿抗gbs2106 IgG几何平均浓度低于对照组(p=0.012)。
核心结论
- 婴儿血清抗gbs2106 IgG与侵袭性B族链球菌病风险呈反向关联,提示gbs2106蛋白为潜在疫苗候选。
研究设计与样本
- 在南非基于出生队列的嵌套病例对照研究,病例经医院监测系统补充纳入。
- 采用流式细胞术检测gbs2106表面表达,Luminex平台珠基法测定母血、脐血或婴儿血抗gbs2106 IgG。
主要发现
- gbs2106基因存在于对照组母亲定植分离株和婴儿侵袭性分离株的全部样本中。
- gbs2106蛋白在母亲定植分离株和侵袭性分离株中的表达率分别为81.6%(71/87)和82.2%(48/58)。
- 母血与脐血抗gbs2106 IgG强正相关(r=0.855,p<0.0001),脐血与母血几何平均浓度比值为0.9(IQR 0.7-1.1)。
- 病例组婴儿血清抗gbs2106 IgG几何平均浓度为158.7 AU/ml(95%CI:102.3-246.2),低于对照组的304.8 AU/ml(95%CI:226.8-409.8),p=0.012。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human immunoglobulin G (IgG) directed against Group B streptococcus (GBS) epitopes is transferred transplacentally from the mother to the fetus. A GBS putative protein, gbs2106, has been previously identified as a potential GBS protein antigen vaccine candidate. However, its genetic prevalence and surface expression in GBS-isolates has not been evaluated. In this study, we evaluated the prevalence, surface expression and association of maternal-acquired serum anti-gbs2106 IgG in newborns and risk reduction of infant invasive GBS disease through to 90 days of age in a South African-based cohort. METHODS: We conducted a nested case-control study within a previously established birth cohort that was designed to investigate serological markers associated with risk reduction of invasive GBS disease. In the parent study, additional cases were identified through a hospital surveillance system which included infants diagnosed with culture-confirmed invasive GBS disease outside the original cohort study. In this current study, surface expression of gbs2106 was analyzed on recto-vaginal colonizing isolates from mothers whose infants remained healthy, and on isolates from infants who developed invasive GBS disease. Flow cytometry was used to determine surface expression levels. The anti-gbs2106 IgG in maternal and infant or cord blood was measured using a bead-based assay on the Luminex platform. RESULTS: The gbs2106 gene was present on all colonizing GBS-isolates from women in the control group and infant invasive GBS-isolates. The gbs2106 protein was expressed on 81.6 % (71/87) and 82.2 % (48/58) of maternal colonizing isolates and invasive GBS-isolates, respectively. There was a strong positive correlation (r = 0.855, p < 0.0001) of maternal and cord serum anti-gbs2106 IgG levels, with the combined cord to maternal anti-gbs2106 IgG geometric mean concentration ratio being 0.9 (IQR 0.7-1.1). Serum anti-gbs2106 IgG geometric mean concentrations in the infants were lower among the invasive disease cases (158.7 arbitrary units [AU]/ml; 95 %CI: 102.3-246.2) compared with controls (304.8 AU/ml; 95 %CI: 226.8-409.8; p = 0.012). CONCLUSION: Our study demonstrates an inverse association between infant serum anti-gbs2106 IgG and risk of invasive GBS disease, indicating gbs2106 protein as a potential vaccine candidate.
引用
- Gent V, Dhar N, Izu A, et al. Association of serum anti-gbs2106 protein immunoglobulin G (IgG) in newborns and risk reduction of invasive group B streptococcus disease during early infancy. Vaccine. 2025. PMID: 40088514. doi:10.1016/j.vaccine.2025.127016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。